- REGENXBIO (RGNX, Financial) to host a webcast on June 5, 2025, presenting new data from their Phase I/II AFFINITY DUCHENNE trial.
- The trial focuses on RGX-202, a next-gen gene therapy for Duchenne muscular dystrophy.
- Dr. Aravindhan Veerapandiyan from Arkansas Children's Hospital will present the interim functional data.
REGENXBIO Inc. (RGNX) has announced a webcast scheduled for June 5, 2025, at 8:00 a.m. EDT to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202. RGX-202 is the company's next-generation investigational gene therapy aimed at treating Duchenne muscular dystrophy.
The webcast will feature a presentation by the trial's principal investigator, Dr. Aravindhan Veerapandiyan, from Arkansas Children's Hospital. Stakeholders and investors can access the live webcast through the Investors section of REGENXBIO's official website at www.regenxbio.com. For those unable to attend the live session, an archived replay will be made available for approximately 30 days following the event.
REGENXBIO is known for pioneering AAV gene therapy, with a strong pipeline targeting rare and retinal diseases. Their efforts with RGX-202 underscore their commitment to potentially transformative treatments for conditions like Duchenne muscular dystrophy.
